Inclisiran a better drug in treating familial hypercholesterolemia - Video

Published On 2022-02-02T19:29:04+05:30 | Updated On 2 Feb 2022 7:29 PM IST

Overview

Familial hypercholesterolemia approximately affects 1 in 200 to 1 in 250 people in most countries and is thought to be the most common inherited condition affecting the heart and blood vessels. It is a serious cause of heart attack worldwide and causing a serious threat in global health management.

The ORION- 4 trial in the Journal of the American College of Cardiology reveals that pooled safety and efficacy data of inclisiran, when given twice yearly in addition to maximally tolerated statin therapy with or without other LDL-Cholesterol lowering agents, is an effective, safe, and well-tolerated treatment to lower LDL-Cholesterol in adults with heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, or atherosclerotic cardiovascular disease risk equivalents.

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751